Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and ...

They aren't just "pandemic stocks." ...

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

Shares of Moderna MRNA rose about 4% on Friday after the company announced that the EMA’s Committee for Medicinal Products ...

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day. This change lagged the S&P 500's daily loss of 1.51%. On the other hand, the Dow registered ...